Connective Tissue Disease–Associated Interstitial Lung Disease : Evaluation and Management - 01/08/19

Doi : 10.1016/j.ccm.2019.05.008

Danielle Antin-Ozerkis, MD ^a,^⁎ , Monique Hinchcliff, MD, MS ^b
^a Section of Pulmonary and Critical Care Medicine, Yale School of Medicine, PO Box 208057, New Haven, CT 06520-8057, USA
^b Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, PO Box 208031, New Haven, CT 06520-8031, USA

^∗Corresponding author.

Résumé

Interstitial lung disease is common among patients with connective tissue disease and is an important contributor to morbidity and mortality. Infection and drug toxicity must always be excluded as the cause of radiographic findings. Immunosuppression remains a mainstay of therapy despite few controlled trials supporting its use. When a decision regarding therapy initiation is made, considerations include an assessment of disease severity as well as a determination of the rate of progression. Because patients may have extrathoracic disease activity, a multidisciplinary approach is crucial and should include supportive and nonpharmacologic management strategies.

Le texte complet de cet article est disponible en PDF.

Keywords : Interstitial lung disease, Connective tissue disease, Pulmonary fibrosis, Immunosuppression, Scleroderma, Rheumatoid arthritis, Supportive care

Plan

Disclosures: Dr D. Antin-Ozerkis has received grants and contracts to her institution from Biogen, Boehringer Ingelheim, FibroGen, Genentech, and Promedior. Dr M. Hinchcliff has received grants and research support from Gilead Sciences and Actelion Pharmaceuticals.